Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

erence, Consultant Hematologist and Head of the CLL Unit at The Royal Marsden NHS Foundation Trust in London. "Equally important, the exciting efficacy and safety data that we are seeing for this drug in these studies underscore the significant progress we are making in our quest to better understand and attack the specific cellular targets responsible for CLL, particularly in these vulnerable patient populations."

National Cancer Institute, "SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia," http://seer.cancer.gov/statfacts/html/clyl.html (Accessed October 2012). Gribben, J.G., "How I treat CLL up front," Blood 115, no. 2 (2009): 187-197.

This press conference will take place on Saturday, December 8, at 8:00 a.m. EST

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment Nave (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in Phase Ib/II Study [Abstract 189]

New research demonstrates that a novel investigational therapeutic agent called ibrutinib may be an effective and safe targeted treatment option for previously untreated, hard-to-treat, and relapsed patients with chronic lymphocytic leukemia (CLL).

Primary treatment for CLL includes a combined chemotherapy-based regimen with fludarabine and cyclophosphamide, along with the immune therapy rituximab. While rituximab is effective, it is generally not well tolerated among elderly patients. Treatment with this drug also compromises the immune system by attacking both cancerous and normal cells, putting patients at risk for a range of infection
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The North America Phytochemicals & Plant Extracts Market ... in North America with analysis and forecast of revenue. This ... in 2012 to $930.1 million by 2018, at a CAGR ... TOC of the North America phytochemicals & plant extracts market ... It also provides a glimpse of the segmentation in the ...
(Date:7/31/2014)... The North American Colorants Market ... North America with analysis and forecast of volume ... North American Colorants Market report, to get an ... provides a glimpse of the segmentation in the ... various tables and figures. , http://www.micromarketmonitor.com/market/americas-colorants-8463333110.html ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Many teens never outgrow their ... pain can persist for years, affecting teens, participation in ... left untreated, so-called growing pains can become chronic, the ... that one in three young people between the ages ... their knees," said Michael Skovdal Rathleff, a physiotherapist from ...
(Date:7/31/2014)... 2014 i2i Systems announced today it ... (SAS) to provide a robust patient referral database ... is one of the largest independent software companies in ... 40,000 patients are seen annually in its on-site HCC ... primary care, providers at the SAS HCC refer patients ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 With the brand ... a new lecture series featuring the “reality model” ... National Park, a more affordable resort pricing structure, and a ... Co-founder, says, “We have always had a great weight loss ... that differentiate Fitness Ridge. We want to change the way ...
Breaking Medicine News(10 mins):Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Teen 'Growing Pains' May Persist For Years 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 3Health News:Weight Loss Destination, the Biggest Loser Resort in Utah, Rebrands as Fitness Ridge 2
... male veterans suffering from chronic obstructive pulmonary disease (COPD), ... cancer, researchers found that regular use of high dose ... cancer. ,David H. Au, M.D., M.S., of the ... along with five associates found that among 10,474 patients ...
... testosterone, which plays a key role in health and ... ,People suffering with Alzheimer's lack the ability to ... As the disease progresses, individuals may also experience changes ... agitation, as well as delusions or hallucinations. ...
... has over the years been a high source of nutrition ... that can be eaten in several forms, it is the ... With Easter just round the corner an animal rights group ... urging people not to eat eggs. ,Volunteers of ...
... fish varieties, is increasing all along the coastal regions in ... to it every year, it is estimated. // ... damage that pollution and global warming are inflicting on the ... of popular fish types, including grouper and barracuda, live near ...
... last year, has left Health Trusts short of nearly ?56million, ... from a local survey of health trusts show that almost ... money than they had expected to get under the new ... shortage, PCT may try to re allocate money from other ...
... overweight and obese individuals, the incidence of asthma increases ... weight, according to a meta-analysis of seven studies on ... first issue for April 2007 of the American Journal ... American Thoracic Society. ,E. Rand Sutherland, ...
Cached Medicine News:Health News:High Dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 2Health News:Global Warming Could Increase Exotic Fish Poisoning 2Health News:Asthma Incidence Shows a 50 Percent Increase in Fat People 2
(Date:7/31/2014)... WASHINGTON , July 31, 2014  CVS/pharmacy ... first pharmacy in the nation to earn the ... health care accreditation organization that establishes quality standards ... Longs Drug Store locations nationwide have earned this ... accreditation programs. Its Community Pharmacy Accreditation Program was ...
(Date:7/31/2014)... Mass., July 31, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenue of $70.1 million for the second quarter ... $50.8 million in revenue for the same period of ... ® Ventricular Assist Systems were sold globally compared ...
(Date:7/31/2014)... 2014 Second Quarter Total Revenue $2.0 billion; an increase of ... 4% for same store sales and 8% pro forma, excluding ... , 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, ... Operating Cash Flow $376 million; Adjusted Operating Cash Flow $500 ... Launched 17 new products in the U.S. year-to-date , ...
Breaking Medicine Technology:CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 2CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23
... International Partnership for Microbicides, issued the following statement ... and effectiveness study of BufferGel and PRO2000 (0.5 ... Microbicide Trials Network, a worldwide collaborative group funded ... released final results from its Phase II/IIb safety ...
... Only Approved Platelet Producer in Europe Represents New ... Feb. 6 Amgen (Nasdaq: AMGN ... has granted marketing authorisation for Nplate(R) (romiplostim) for ... thrombocytopenic purpura (ITP) patients who are refractory to ...
Cached Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8
Quick Release Holder designed for the 8000 Series Microtome to hold hardboard squares....
Steel Knife with box for the Series 8000 Sliding Microtome. C-Profile, 240 x 33 x13m, 22 Degree angle, tapped to accept holder for Shandon knife sharpener....
... new SureCut M3500 Radial Microtome has a look ... and a range of functions and capabilities that ... Based on years of experience and knowledge but ... the SureCut M3500 Microtome will be the answer ...
Spare fuse set...
Medicine Products: